Bank of America’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Bank of America’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1	Closed	–	–	8611
2022 Q2	$0	Buy	+1	New	+$5	﹤0.01%	8835
2022 Q1	–	Sell	-3	Closed	-$29	–	9171
2021 Q4	$0	Buy	+3	New	+$43	﹤0.01%	9073
2021 Q3	–	Sell	-1	Closed	-$16	–	8706
2021 Q2	$0	Hold	1	–	–	﹤0.01%	8446
2021 Q1	$0	Hold	1	–	–	﹤0.01%	8083
2020 Q4	$0	Sell	1 -1	-50%	-$20	﹤0.01%	7625
2020 Q3	$0	Buy	2 +1	+100%	+$37	﹤0.01%	7433
2020 Q2	$0	Sell	1 -42	-98%	-$1.64K	﹤0.01%	7399
2020 Q1	$2K	Buy	+43	New	+$6.08K	﹤0.01%	6686
2019 Q4	–	Hold	0	–	–	–	7728
2019 Q3	–	Hold	0	–	–	–	7763
2019 Q2	–	Hold	0	–	–	–	7657
2019 Q1	–	Hold	0	–	–	–	7735
2018 Q4	–	Hold	0	–	–	–	7727
2018 Q3	–	Hold	0	–	–	–	7707
2018 Q2	–	Hold	0	–	–	–	7597
2018 Q1	–	Hold	0	–	–	–	6934
2017 Q4	–	Hold	0	–	–	–	6891
2017 Q3	–	Sell	-1	Closed	-$30.7K	–	6796
2017 Q2	$58K	Hold	1	–	–	﹤0.01%	5815
2017 Q1	$61K	Hold	1	–	–	﹤0.01%	5837
2016 Q4	$56K	Hold	1	–	–	﹤0.01%	5879
2016 Q3	$83K	Buy	+1	New	+$125K	﹤0.01%	5515
2016 Q2	–	Hold	0	–	–	–	5805
2016 Q1	–	Sell	-1	Closed	-$107K	–	5709
2015 Q4	$68K	Buy	+1	New	+$149K	﹤0.01%	5902
2015 Q3	–	Sell	-1	Closed	-$234K	–	5773
2015 Q2	$154K	Buy	+1	New	+$264K	﹤0.01%	5377

Other funds holding NVIV

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America's NVIV Position: Q3 2022 in Review

Bank of America sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q3 2022, closing a stake of 1 share.

Bank of America first reported a position in NVIV in Q2 2015 and held it in 14 quarters. The position peaked at $154K in Q2 2015. 16 funds tracked by Wall St. Rank hold NVIV as of Q3 2022.

Bank of America reported no remaining InVivo Therapeutics Holdings Corp position as of Q3 2022 after selling out during the quarter.
Bank of America sold 1 InVivo Therapeutics Holdings Corp share in Q3 2022.
Bank of America first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 14 quarters.
Bank of America's InVivo Therapeutics Holdings Corp position peaked at $154K in Q2 2015.
16 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q3 2022.

Based on Bank of America's 13F filing for Q3 2022, filed 14 Nov 2022.